Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120547 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
A Phase 1 study, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02120547 is a Phase 1 study that has completed, run by Tobira Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT02120547, a Phase 1 study, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
To determine whether CVC exposures are altered in subjects with impaired hepatic function, compared to subjects with normal hepatic function. The results will help guide the clinical use of CVC in patients with hepatic impairment, determine the extent of PK changes, if any, and identify the potential need for dose adjustments of CVC in this population.
Interventions
- DRUG Cenicriviroc in mild liver impaired
- DRUG Cenicriviroc in moderate liver impaired
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120547
The ClinicalTrials.gov registry entry for NCT02120547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cenicriviroc in mild liver impaired is the first listed.
NCT02120547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120547 about?
NCT02120547 is a clinical study titled "Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment". To determine whether CVC exposures are altered in subjects with impaired hepatic function, compared to subjects with normal hepatic function. The results will help guide the clinical use of CVC in patients with hepatic impairment, determine the extent of PK changes, if any, and identify the potentia...
What is the current status of trial NCT02120547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-03. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02120547?
The interventions under investigation include: Cenicriviroc in mild liver impaired (DRUG), Cenicriviroc in moderate liver impaired (DRUG).
Who is sponsoring clinical trial NCT02120547?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.